Clinical Trials Browser

Phase 2 × Salivary Gland Neoplasms × Docetaxel × Clear all

NCT03360890 2026-03-13

iPRIME

Phase 2 Active not recruiting

Salivary Gland Neoplasms, Thyroid Neoplasms

NCT05408845 2026-01-14

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Phase 2 Recruiting

Salivary Gland Neoplasms

NCT06145308 2025-09-15

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2 Recruiting

Salivary Gland Neoplasms

NCT00040807 2023-06-18

Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms

NCT05008237 2021-08-17

Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study

Phase 2 Unknown

Salivary Gland Neoplasms

NCT00003565 2016-07-14

Docetaxel in Treating Patients With Solid Tumors

Phase 2 Completed

BreastCNSGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Nasopharyngeal Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma